• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Serbia Pharmaceuticals and Healthcare Report Q3 2012 - Product Image

Serbia Pharmaceuticals and Healthcare Report Q3 2012

  • ID: 2199763
  • July 2012
  • Region: Serbia
  • 96 pages
  • Business Monitor International

The Serbia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Serbia's pharmaceuticals and healthcare industry.

BMI View: The short-term outlook for the Serbian pharmaceutical market will continue to be clouded by corruption, debts accrued by the country’s health insurance agency and also the liquidity of the country’s wholesalers. Additionally, the challenging economic situation will hamper the purchase of necessary medicines by the majority of the cash-strapped population, especially as out-of-pocket contribution to healthcare in general stands at almost 40%. We therefore envisage generic medicines gaining further ground on their patented counterparts, although imports will continue to play an important part in the overall market.

Headline Expenditure Projections
- Pharmaceuticals: RSD74.78bn (US$1.02mn) in 2011 to RSD79.30bn (US$934mn) in 2012; +6.0% in local currency terms and -8.4% in US dollar terms. Forecast slightly lower from Q212 due to macroeconomic factors.

- READ MORE >

Note: Product cover images may vary from those shown

Executive Summary 5

SWOT Analysis 7

Serbia Pharmaceuticals And Healthcare Industry SWOT 7

Serbia Political SWOT 8

Serbia Economic SWOT 8

Serbia Business Environment SWOT 8

Pharmaceutical Risk/Reward Ratings 10
Table: Emerging Europe Regional Pharma Risk/Reward Ratings for Q312 10

Rewards 12

Risks 12

Serbia – Market Summary 14

Regulatory Regime 15
Table: The Number of Products on the Drugs List 15

Corruption In The Healthcare Sector 16

Intellectual Property Environment 18

Pricing Regime 19

Price Developments 20

Reimbursement Regime 21
Table: Leading Suppliers of Medicines to RZZO, by Value (RSDmn) 23
Table: Cost of Prescriptions Covered by RZZO by Anatomical Therapeutic Chemical (ATC) Classification (RSD '000) 23

Industry Developments 24

Epidemiology 24

Communicable Diseases 24

Non-Communicable Diseases 25

Healthcare Sector 26
Table: Major General And Specialised Hospitals 26

Healthcare Insurance 28

Healthcare Debts 29

Clinical Trials 30

Medical Devices 31
Table: Medical Device Classification In Serbia 32

Industry Forecast Scenario 33

Overall Market Forecast 33
Table: Pharmaceutical Sales Indicators 2008-2016 34

Healthcare Market Forecast 35
Table: Healthcare Expenditure Indicators 2008-2016 36
Table: Healthcare Governmental Indicators 2008-2016 36
Table: Healthcare Private Indicators 2008-2016 37

Key Growth Factors – Macroeconomic 38
Table: Prescription Drug Sales Indicators 2008-2016 45
Table: Drug Sales By ATC Classification System 45

Patented Drug Market Forecast 47
Table: Patented Drug Market Indicators 2008-2016 48

Generic Drug Market Forecast 49
Table: Generic Drug Sales Indicators 2008-2016 50

OTC Medicine Market Forecast 51
Table: OTC Medicine Sales Indicators 2008-2016 52

Pharmaceutical Trade Forecast 53
Table: Exports and Imports Indicators 2008-2016 55

Medical Device Market Forecast 56
Table: Medical Devices Sales Indicators 2008-2016 57

Other Healthcare Data Forecasts 58

Key Risks To our Forecast Scenario 58

Competitive Landscape 59

Investment Climate 59

Pharmaceutical Industry 59
Table: Companies Involved In The Serbian Pharmaceutical Industry 60

Domestic Pharmaceutical Industry 60

Domestic Company Activity 62

Foreign Pharmaceutical Industry 63
Table: Proposed Members Of Serbia’s Pharmaceutical Industry Association 63

Foreign Company Activity 64

Pharmaceutical Wholesale And Retail 65

Company Monitor 66

Indigenous Company Profiles 66

Hemofarm (Stada) 66

Galenika 70

Zdravlje Actavis 74

Jugoremedija 77

Multinational Company Profiles 79

Pfizer 79

GlaxoSmithKline 80

Novartis 81

Sanofi-Aventis 82

Merck & Co 83

Krka 84

Demographic Outlook 86
Table: Serbia's Population By Age Group, 1990-2020 ('000) 87
Table: Serbia's Population By Age Group, 1990-2020 (% of total) 88
Table: Serbia's Key Population Ratios, 1990-2020 89
Table: Serbia's Rural And Urban Population, 1990-2020 89

Glossary 90

BMI Methodology 92

How We Generate Our Pharmaceutical Industry Forecasts 92

Pharmaceuticals Business Environment Ratings 93

Risk/Reward Ratings Methodology 93

Ratings System 93
Table: Pharmaceutical Business Environment Indicators 94

Weighting 94
Table: Weighting Of Components 95

Sources 95

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos